Here's What Analysts Are Forecasting For ClearPoint Neuro, Inc. (NASDAQ:CLPT) After Its Full-Year Results
Here's What Analysts Are Forecasting For ClearPoint Neuro, Inc. (NASDAQ:CLPT) After Its Full-Year Results
Shareholders of ClearPoint Neuro, Inc. (NASDAQ:CLPT) will be pleased this week, given that the stock price is up 19% to US$7.21 following its latest full-year results. Revenues came in at US$24m, in line with forecasts and the company reported a statutory loss of US$0.90 per share, roughly in line with expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on ClearPoint Neuro after the latest results.
ClearPoint Neuro, Inc.（納斯達克股票代碼：CLPT）的股東本週將感到高興，因爲在最新的全年業績公佈後，股價上漲了19％，至7.21美元。收入爲2400萬美元，符合預期，該公司報告的法定虧損爲每股0.90美元，大致符合預期。對於投資者來說，盈利是一個重要時刻，因爲他們可以追蹤公司的業績，查看分析師對明年的預測，看看對公司的情緒是否發生了變化。讀者會很高興得知我們已經彙總了最新的法定預測，以了解分析師在最新業績公佈後是否改變了對ClearPoint Neuro的看法。
Taking into account the latest results, the consensus forecast from ClearPoint Neuro's three analysts is for revenues of US$30.3m in 2024. This reflects a substantial 26% improvement in revenue compared to the last 12 months. The loss per share is expected to ameliorate slightly, reducing to US$0.76. Before this earnings announcement, the analysts had been modelling revenues of US$30.4m and losses of US$0.80 per share in 2024. So there seems to have been a moderate uplift in analyst sentiment with the latest consensus release, given the upgrade to loss per share forecasts for this year.
考慮到最新業績，ClearPoint Neuro的三位分析師的共識預測是，2024年的收入爲3,030萬美元。這反映了與過去12個月相比，收入大幅增長了26％。預計每股虧損將略有改善，降至0.76美元。在此業績公佈之前，分析師一直在模擬2024年的收入爲3,040萬美元，每股虧損爲0.80美元。因此，鑑於今年的每股虧損預測已上調，最新共識發佈後，分析師的情緒似乎略有提高。
The average price target held steady at US$10.00, seeming to indicate that business is performing in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on ClearPoint Neuro, with the most bullish analyst valuing it at US$11.00 and the most bearish at US$9.00 per share. This is a very narrow spread of estimates, implying either that ClearPoint Neuro is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.
平均目標股價穩定在10.00美元，這似乎表明業務表現符合預期。但是，這並不是我們可以從這些數據中得出的唯一結論，因爲一些投資者在評估分析師目標股價時也喜歡考慮估計值的差異。對ClearPoint Neuro有一些不同的看法，最看漲的分析師將其估值爲11.00美元，最看跌的爲每股9.00美元。這與估計值的差距非常小，這意味着ClearPoint Neuro是一家易於估值的公司，或者——更有可能是——分析師嚴重依賴一些關鍵假設。
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that ClearPoint Neuro's rate of growth is expected to accelerate meaningfully, with the forecast 26% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 21% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 7.8% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect ClearPoint Neuro to grow faster than the wider industry.
從現在的大局來看，我們可以理解這些預測的方法之一是看看它們如何與過去的業績和行業增長預期相比較。從最新估計中可以明顯看出，ClearPoint Neuro的增長率預計將大幅加速，預計到2024年底的年化收入增長率爲26％，明顯快於過去五年中每年21％的歷史增長。相比之下，我們的數據表明，預計類似行業的其他公司（有分析師報道）的收入將以每年7.8％的速度增長。顯而易見，儘管增長前景比最近更加光明，但分析師也預計ClearPoint Neuro的增長速度將超過整個行業。
The Bottom Line
底線
The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
最明顯的結論是，分析師對明年虧損的預測沒有改變。幸運的是，他們還再次確認了收入數字，這表明收入數字符合預期。此外，我們的數據表明，收入的增長速度預計將快於整個行業。共識目標價格沒有實際變化，這表明根據最新估計，該業務的內在價值沒有發生任何重大變化。
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for ClearPoint Neuro going out to 2026, and you can see them free on our platform here..
話雖如此，公司收益的長期軌跡比明年重要得多。在Simply Wall St，我們有分析師對ClearPoint Neuro到2026年的全方位估計，你可以在我們的平台上免費看到這些估計。
You still need to take note of risks, for example - ClearPoint Neuro has 3 warning signs we think you should be aware of.
例如，您仍然需要注意風險——ClearPoint Neuro有3個警告信號，我們認爲您應該注意。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎？對內容感到擔憂？直接聯繫我們。 或者，給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論，我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議，也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意，我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之，華爾街沒有持有任何上述股票的頭寸。
譯文內容由第三人軟體翻譯。